Drug Database
Back to search

Netherlands· NL-685d02f53563

Kirsty 100 IE/ml, oplossing voor injectie

A insulin aspart product containing insuline aspart, registered in Netherlands by Biosimilar Collaborations Ireland Limited. The same ATC class is registered in 11 of our 19 countries.

ATC A10AB05

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedKirsty 100 IE/ml, oplossing voor inje…ATCA10AB05REGISTER NO.NL-685d02f53563PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about insuline aspartAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Insulin aspart is registered in 11 of 19 countries.

Countries holding a registration under ATC A10AB05 (insulin aspart), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search insulin aspart products by name

Insulin aspart · ATC A10AB05

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
INSULINE ASPART
Manufacturer
Biosimilar Collaborations Ireland Limited
Country
Netherlands (NL)
ATC code
A10AB05
ATC class
Insulin aspart
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/20/1506

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

434 interactions on record for insulin aspart.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check insulin aspart against other medicinesHow interaction checks work

Insulin aspart · interactions on record

434 records

  • 15 severe
  • 368 moderate
  • 50 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • PrednisoloneA07EA01moderate

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Insulin aspart in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin aspart products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Dazparda, Fiasp
  • Liechtenstein · Dazparda, Insulin Aspart Sanofi
  • Norway · Dazparda, Fiasp

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4dcdeace-7a3a-489f-a49c-5881d9cd70c1
GET /v1/drugs/4dcdeace-7a3a-489f-a49c-5881d9cd70c1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/kirsty-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Insulin Aspart",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp125762",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 2-WATER (E 339)",
    "FENOL",
    "GLYCEROL 85 PER CENT (E 422)",
    "METACRESOL",
    "NATRIUMCHLORIDE",
    "NATRIUMHYDROXIDE (E 524)",
    "WATER VOOR INJECTIE",
    "ZINKDICHLORIDE 0-WATER",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "INSULINE ASPART"
  ],
  "leaflet_url": null,
  "authorised_at": "2021/02/05",
  "procedure_number": "EMEA/H/C/004965",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/20/1506",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about insulin aspart.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console